First-in-human study of a novel cell death tracer [^99mTc]Tc-Duramycin: safety, biodistribution and radiation dosimetry in healthy volunteers.

ABSTRACT:

Background

Imaging of cell death can provide an early indication of treatment response in cancer. [^99mTc]Tc-Duramycin is a small-peptide SPECT tracer that recognizes both apoptotic and necrotic cells by binding to phosphatidylethanolamine present in the cell membrane. Preclinically, this tracer has shown to have favorable pharmacokinetics and selective tumor accumulation early after the onset of anticancer therapy. In this first-in-human study, we report the safety, biodistribution and internal radiation dosimetry of [^99mTc]Tc-Duramycin in healthy human volunteers.

Results

Six healthy volunteers (3 males, 3 females) were injected intravenously with [^99mTc]Tc-Duramycin (dose: 6 MBq/kg; 473 ± 36 MBq). [^99mTc]Tc-Duramycin was well tol

SUBMITTER: Metelerkamp Cappenberg T 

PROVIDER: S-EPMC10468453 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature